What We're Reading: Page 94
Industry reads hand-picked by our editors
Aug 03, 2023
-
The New York Times
Amid Signs of a Covid Uptick, Researchers Brace for the ‘New Normal’
-
Bloomberg
China Drug-Price Negotiations Offers Glimpse Into Future for Companies in US
-
The Financial Times
Lawsuit alleges blockbuster weight-loss drugs cause ‘stomach paralysis’
-
Fierce Biotech
It’s Goose Data’s (online) world, and biotechs are just sitting ducks
Aug 02, 2023
Aug 01, 2023
-
JAMA
Are New Alzheimer Drugs Better Than Older Drugs?
-
The Wall Street Journal
Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease
-
Healthcare Dive
CVS to lay off 5K employees amid cost pressures
-
The Baltimore Sun
Family of Henrietta Lacks settles HeLa cell lawsuit with biotech giant, lawyer says
Jul 31, 2023
-
Reuters
Drugmakers go under the skin, skirting early US Medicare price negotiations
-
San Francisco Business Times
FibroGen limits rare-disease drug’s access after clinical trial failure. Some parents say it was saving their kids’ lives
-
The Washington Post
Lifesaving HIV program faces a new threat: U.S. abortion politics
Jul 28, 2023
-
The Wall Street Journal
Biotech Stocks Join AI-Fueled Rally
-
Fierce Biotech
FDA CBER Chief Marks overrules staff drug reviewers ‘with trepidation’
-
Science
In some scientific papers, words expressing uncertainty have decreased
Jul 27, 2023
Jul 26, 2023
-
The Wall Street Journal
A Surprising Beneficiary of New Alzheimer’s Drugs: GE HealthCare
-
Evaluate Vantage
GSK admits anaemia defeat
-
Financial Times
UK billionaire Joe Lewis surrenders to US authorities on insider trading charges
-
Stat News
Asian American doctors, overrepresented in medicine, are largely left out of leadership